Ferrari E, Fioravanti M, Patti A L, Viola C, Solerte S B
Pharmatherapeutica. 1987;5(1):26-39.
Twenty-one insulin-dependent and 30 non-insulin-dependent diabetic patients were treated over 48 months with pentoxifylline ('Trental' 400) 1200 mg/day orally. All patients had haemorheological alterations and vascular complications. A marked improvement in erythrocyte deformability and a reduction in plasma fibrinogen levels was already evident after 6 months of therapy; these improvements were maintained throughout the 48 months of the study and were independent of short-term and long-term glycometabolic changes. The normalization of blood rheology pattern was associated with a significant decrease in total urinary protein excretion rate and in urinary albumin excretion rate. An improvement in both microvascular, i.e., retinopathy and nephropathy, and macrovascular, i.e. ischaemic heart disease and peripheral occlusive arterial disease, complications was demonstrated after the long-term trial with pentoxifylline. No side-effects occurred during the observation period. These data suggest that pentoxifylline may have an important role in both the treatment of diabetic haemorheological changes and renal disorders and in the prevention of accompanying degenerative vascular complications.
21例胰岛素依赖型糖尿病患者和30例非胰岛素依赖型糖尿病患者接受了为期48个月的己酮可可碱（“曲克芦丁”400）治疗，口服剂量为每日1200毫克。所有患者均有血液流变学改变和血管并发症。治疗6个月后，红细胞变形能力明显改善，血浆纤维蛋白原水平降低；这些改善在整个48个月的研究中得以维持，且与短期和长期糖代谢变化无关。血液流变学模式的正常化与总尿蛋白排泄率和尿白蛋白排泄率的显著降低相关。长期使用己酮可可碱试验后，微血管并发症（即视网膜病变和肾病）和大血管并发症（即缺血性心脏病和外周动脉闭塞性疾病）均有改善。观察期内未出现副作用。这些数据表明，己酮可可碱在治疗糖尿病血液流变学改变和肾脏疾病以及预防伴随的退行性血管并发症方面可能具有重要作用。
